Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read MoreDec 14, 2022
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read MoreDec 9, 2022
Almost one-third of residents with gout living in aged care facilities did not receive...
Read MoreDec 6, 2022
Early findings from the PROTECT trial,1 presented at the 2022 American Society of Nephrology’s...
Read MoreDec 5, 2022
At the 2022 American College of Rheumatology, ACR Convergence meeting, Dr. Sarah Black, a...
Read MoreDec 2, 2022
Past observational studies have shown a link between hypertension and gout, but whether a causal relationship existed was unclear, according to Chang-Fu Kuo, MD, PhD. For a study published in Arthritis Research & Therapy,...
Read MoreDec 1, 2022
Patients with aggressive hematological malignancies and second primary malignancies can develop in...
Read MoreDec 1, 2022
For a study, researchers sought to determine if ibrutinib combined with fludarabine,...
Read MoreNov 30, 2022
FIRE is a noninterventional, multicenter observational trial of patients in France receiving...
Read MoreNov 30, 2022
With the development of cutting-edge drugs like Ibr, the treatment landscape for CLL/SLL has...
Read MoreNov 30, 2022
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read MoreNov 29, 2022
At the 2022 American College of Rheumatology Convergence meeting, Michael Pillinger, MD, presented...
Read MoreNov 29, 2022
For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such as abdominal pain...
Read MoreNov 29, 2022
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various prognostic factors were known, including the revised international prognostic index (R-IPI), MYC/BCL2 overexpression by IHC,...
Read MoreNov 28, 2022
Patients with IBS-D had significantly higher percentages of moderate to severe anxiety and depression and considerably lower HRQOL versus controls. For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such...
Read MoreNov 28, 2022
A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...
Read MoreNov 28, 2022
For tailored therapy selection and result optimization in diffuse large B-cell lymphoma (DLBCL),...
Read MoreNov 21, 2022
Results from the MIRROR RCT trial, presented at the 2022 American Society of Nephrology’s Kidney...
Read MoreNov 18, 2022
Gout flares occurred in 18% of patients with comorbid gout who were hospitalized for COVID-19,...
Read MoreNov 15, 2022
IgG-based elimination diets using a novel diagnostic tool to guide therapy may be beneficial to...
Read MoreNov 15, 2022
For patients with gout, urate-lowering therapy (ULT) increases the risk of hospitalizations within...
Read More